Table of Contents

AI is capable of processing assets instantly in medical, legal, and regulatory (MLR) review, but humans are scaling its use only at the speed of trust in outcomes and risk tolerance. As a result, content leaders are discussing how the success of AI in MLR depends as much on supporting behavioral change as on refining technical workflows.

Those who successfully navigate this shift will use AI to achieve high-autonomy or ‘touch-free’ MLR. This approach elevates the value of human expertise so reviewers act as strategic advisors focused on complex content and true regulatory nuances.

“People are tinkering with AI. It’s improving how we work, make decisions, and ultimately our ability to communicate meaningfully with patients and customers. We have tangible evidence-based tools at our disposal that could help us crank as the commercial engine we are.”

Christian Furler O'Brien

Director, U.S. Promotional Review Process (PReP), Label & Launch Operations, Bristol Myers Squibb

The core MLR tension delaying AI adoption

In many biopharmas, a critical tension remains with AI adoption: Nearly half of content professionals express hesitation about using it in the formal MLR workflow due to the potential liabilities. Attitudes about AI can become polarized in a given team, ranging from enthusiastic advocates to highly vocal skeptics.

One leader sees three layers of operational friction in this internal divide:

  1. Individual reviewers need to feel personally confident and safe enough to engage in conversations about AI capabilities and human replacement fears.
  2. Teams and cross-functional units require open, collaborative conversations to redefine day-to-day workflows and shared accountability.
  3. Organizations need robust AI governance models, system compliance validation, and the progressive culture necessary to scale the technology safely.

The business imperative: Elevate experts to expand review capacity

With MLR professionals in a wait-and-see phase of AI adoption, the technology remains confined to isolated pilots. However, caution comes at a cost. Delaying AI adoption doesn’t just equate to missed efficiencies; it could mean market-share loss and higher operating expenses compared to AI-enabled peers.

Focusing highly trained experts on quality control and basic edits slows the entire content pipeline. This manual churn also underuses the very expertise needed to protect your organization in an era of increased regulatory scrutiny.

The new industry imperative is to scale omnichannel content without overwhelming human review capacity or increasing organizational risk. AI provides a path to deliver tailored information to patients and healthcare professionals (HCPs) faster and more efficiently.

“We need to transition to a model where the AI agent picks up more and more of the workload, eventually leading to full AI automation. Over the next few years, the challenge is figuring out how to move away from our current manual processes and manage those transitions.” — Global Content Strategy Leader

3 Pillars of AI adoption in MLR review

A clear roadmap simplifies the transition to AI in MLR review. Industry leaders across emerging and enterprise biopharmas share practical steps for integrating AI, focusing first on three strategic priorities.

1. Establishing a concrete technology foundation

It’s impossible to build AI into MLR review with a fractured data architecture. As one director of omnichannel marketing operations puts it, “You can’t build ‘the Death Star’ right out of the gate. You must have the data foundations in place first.” Establishing these foundations is about more than just IT architecture; it is the direct mechanism to gain value from AI and ease reviewer apprehension. Leaders are strengthening the infrastructure by:

  • Performing data and asset hygiene: Eliminating non-machine-readable PDFs, inline screenshots, unmapped fonts, and improper metadata tagging ensures AI models review content accurately. This hygiene guarantees the AI application analyzes the correct text, which prevents technical blind spots and builds reviewer confidence.
  • Centralizing the claims library: A structured, digitized claims infrastructure acts as the single source of truth for substantiation and version control, and feeds content creation tools. This ensures the system can definitively handle withdrawals and superseding claims, so outdated data is instantly and reliably flagged.
  • Setting simplified rules and tiers: Converting complex brand and compliance guidelines into explicit logic rules establishes standardized review tiers that identify which content is escalated to which human review functions. Straightforward rules make it easier to add AI in workflows, define its role, and provide reassurance that humans remain in the loop for critical aspects of review.

2. Evolving the review model to align with human behavior

With concrete data foundations in place, organizations can confidently shift their MLR review operations. However, successful AI adoption requires designing workflows that take into account the realities of MLR teams.

Evolving the review model with AI means a shift from a manual, administrative bottleneck into a strategic, high-value process. Instead of expecting human reviewers to inspect every detail of every document, AI allows human experts to focus their expertise by:

  • Prioritizing agentic triage and upstream gates: Organizations are deploying AI agents upstream to auto-assess against specific compliance criteria, enforce formatting compliance, and dynamically route assets based on explicit compliance profiles. This enables agents to reconcile or identify historical reviewer comments, derivative assets, and off-label assessments before a human ever opens the file, providing a comprehensive support system as reviewers take on new accountability.
  • Starting with focus-based review, or the ‘nuance’ shift: Once reviewers trust and use agents to handle ‘below threshold’ checks, they can focus exclusively on the content containing true regulatory nuance. This shift respects their high-level expertise and allows them to act as strategic advisors rather than proofreaders.
  • Ensuring upstream quality enforcement: To protect reviewers from receiving submissions containing errors, organizations are mandating that agency partners pass automated pre-flight checks before assets enter the formal MLR queue. By forcing external vendors to clear automated quality gates, companies ensure that human reviewers spend their valuable time on high-quality, technically compliant submissions.

3. Setting strong governance and a culture supportive of caution

To truly scale AI and overcome inherent risk aversion among some users, organizations can foster a culture that respects caution while providing a clear, supportive path forward. Building trust requires treating AI integration as an exercise in change management rather than just an IT deployment.

  • Addressing the accountability gap: A major hurdle to adoption is the fear of personal liability. Organizations are positioning AI as ‘new labor’ limited to deterministic, low-risk tasks until model accuracy consistently reaches a threshold. To further alleviate reviewer pressure, some companies are even considering shifting accountability models to commercial teams. This shift allows reviewer functions to more easily accept AI into their workflows.
  • Reframing compliance leadership: Biopharmas are transitioning legal and compliance teams from defensive gatekeepers into proactive partners who co-design compliance frameworks and shared risk parameters. By involving these leaders early in the AI setup, organizations turn potential roadblocks into champions of the new process.
  • Structuring change management: Content leaders emphasize cultivating trust and experience through office hours, dedicated resource hubs, weekly tip videos, and phased pilot programs. By expanding use cases for AI over time as trust builds, organizations allow reviewers to experience the system's reliability firsthand before tackling more complex content.

“We offered MLR teams weekly tips and office hours, and built a dedicated online hub containing embedded AI training videos.”

Tareek Turner

Associate Director, HPRC and Content Personalization/Automation, Boehringer Ingelheim

Moving toward touch-free workflows

With the goal of moving toward highly autonomous, touch-free workflows in MLR review, biopharma is closer to delivering ethical, patient-centered marketing — getting the right information and medicines to the right patients. Leaders are experiencing that scaling agentic MLR is most successful when data foundations are solidified, human caution is respected, and the gap between technological potential and organizational trust is bridged. This comprehensive approach is the way to encourage the behavioral change that will allow a shift to new operating models.

The technology and guidance to support this transition — and the foundational work that happens first — are available with Vault AI in PromoMats and Falcon MLR. When organizations prioritize clean data and human-centric governance, MLR teams gain unprecedented productivity as they embrace the speed, accuracy, and efficiency needed for the future of reviews.

See how to modernize MLR with AI and stay on the fastest path to approved content.

Veeva Commercial Summit, Europe

Copenhagen | 18–19 November, 2026

Register Now